News

The American Academy of Ophthalmology will hold its first joint meeting with the Middle East Africa Council of Ophthalmology from Oct. 16 to Oct. 19.

An intracorneal laser procedure using a femtosecond laser is a safe and effective approach for improving the near visual acuity in eyes with low hyperopic presbyopia.

Today's political environment features an unprecedented focus on medical provider fraud and abuse.

Recent results from an ongoing study support the hypothesis that ancestry differences in visual function found in healthy eyes may be signs of early glaucoma.

To communicate with your staff, you need to be sure the message is clear to all.

Attention to a host of preoperative and intraoperative factors can minimize the risk of residual refractive error after cataract surgery, but when a refractive surprise occurs, there are multiple variables to consider before deciding on intervention according to one expert.

'Simultaneous bilateral refractive lens exchange with posterior chamber IOL implantation offers several advantages for patients and surgeons, according to one expert.

Use of the femtosecond laser holds promise for standardizing the 'big bubble' technique and expanding the use of deep anterior lamellar keratoplasty as an alternative to penetrating keratoplasty in eligible patients, according to Luca Buzzonetti, MD.

The relationship between IOP and scleral response could serve as a biomarker for glaucoma and represents one direction glaucoma research is taking.

Dry eye syndrome, now called dysfunctional tear syndrome, is a complex scenario of signs and symptoms.

Phakic IOLs come in many models, but each of these comes with its own challenges.

Relative afferent pupillary defect can be clinically relevant as a red flag indicating that a decrease in visual acuity may be due to something more ominous than a refractive error or media opacity, namely a retinal or optic nerve problem.

With word that Novartis has completed its $28.3 billion acquisition of Nestle S.A.'s shares of Alcon, investment analysts watching the drama unfold expect Novartis and Alcon's Independent Directors Committee will attempt to resolve differences.

Results of a study designed to investigate the addition of microdermabrasion to intense pulsed light therapy in patients with meibomian gland dysfunction and dry eye syndrome corroborate the efficacy of IPL for increasing tear breakup time and decreasing dry eye symptoms but fail to confirm the hypothesis that the benefits of IPL may be enhanced by microdermabrasion, according to Rolando Toyos, MD.

Neither heavy silicone oil or standard silicone oil offers any advantages compared with the other for use as an endotamponade to eyes with inferiorly and posteriorly located proliferative vitreoretinopathy, according to Antonia M. Joussen, MD.

When designing an ophthalmology dispensary, one should attempt to avoid some common errors.

Phase 1 testing is under way to evaluate intravitreal anti-vascular endothelial growth factor gene delivery as a treatment for exudative age-related macular degeneration, according to Abraham Scaria, PhD.

Because elevated IOP essentially is a treatable cause of glaucomatous optic nerve damage, one generally can expect to inhibit progression of disease by lowering IOP.

Monitoring IOP pressure during sleeping hours, two doctors test it out for themselves

The American Society of Cataract and Refractive Surgery (ASCRS) is encouraging eye-care professionals to refer to presbyopia as age-related focus dysfunction.

Iridex Corp. has received a patent for its technology (MicroPulse) designed to provide ophthalmologists with fine dose control of laser energy during eye surgery in patients with glaucoma, diabetic retinopathy, and other retinal disorders.

A combined vitrectomy and phacoemulsification system (Stellaris Procedural Choice Vision Enhancement System, Bausch + Lomb) has been launched worldwide.

The FDA has issued a complete response letter regarding a new drug application (NDA) for oral voclosporin (Luveniq, Lux Biosciences) for the treatment of non-infectious uveitis, according to the company.

The FDA ophthalmic devices panel supports the premarket approval of an implant (iStent Trabecular Micro-Bypass Stent Model GTS-100 L/R, Glaukos) for use in conjunction with cataract surgery to reduce IOP in patients with mild-to-moderate, open-angle glaucoma treated with ocular hypotensive medication.

Thomas G. Frinzi has been named WaveTec Vision?s president and chief executive officer.

Alcon Inc. has received regulatory approval of and has closed the acquisition of LenSx Lasers Inc.

Alcaftadine ophthalmic solution 0.25% (Lastacaft, Vistakon) has been approved by the FDA for the prevention of itching associated with allergic conjunctivitis in patients aged more than 2 years.

OptiMedica Corp. is selling its retina and glaucoma assets to Topcon Corp. to focus exclusively on its cataract-related business.